课题基金 / 基金详情

Aberrant imprinting in humans: Application of genomewide approaches to better understand imprinting regulation and its disturbances

Aberrant imprinting in humans: Application of genomewide approaches to better understand imprinting regulation and its disturbances
人类异常印记:应用全基因组方法更好地了解印记调控及其干扰
批准号:
497659591
负责人:
Professor Dr. Thomas Eggermann, Ph.D.
金额:
$0.0万
依托单位:
依托单位国家:
德国
项目类别:
Research Grants
财政年份:
--
资助国家:
德国
项目状态:
未结题
起止时间:

项目摘要

项目成果

Professor Dr. Thomas Eggermann, Ph.D.的其他基金

相似基金

相关文献

中文摘要
翻译
印迹障碍(ImpDis)包括先天性疾病,其特征在于父母印迹基因的干扰。这些基因从父系或母系等位基因表达,并且干扰由基因组和表观遗传改变组成。ImpDis的临床诊断通常由于缺乏临床特异性而受到阻碍,因为症状可能重叠。ImpDis由四种不同的分子变化引起:其中三种代表经典的分子变化,但表突变包括DNA修饰(例如5-甲基胞嘧啶)。在大多数情况下,表位突变的原因是未知的,但印迹区域本身(顺式因子)以及其他基因组区域(反式因子)的分子改变可能起作用。然而,由于技术限制以及ImpDis的稀缺性,目前缺乏系统的方法。随着NextGenerationSequencing和Longread-Sequencing技术的应用,适用的分析方法现在可用于表观遗传调控和干扰的基因组、结构、表观遗传和转录因子的综合分析。该提案将第二代和第三代测序方法与具有11p15.5和14 q32表观突变的独特患者队列相结合,以解决蛋白质和非蛋白质编码区中等位基因分辨率的基因组和表观遗传变异。确定ImpDis分子基础的策略包括(a)对11p15.5和14 q32表位突变携带者进行全基因组甲基化分析,以确定多位点印迹干扰(MLID)并区分ImpDis亚组。(b)鉴定引起MLID和孤立表突变的顺式和反式因子的基因组变体。(c)一次覆盖整个差异甲基化区域的长距离单分子水平等位基因特异性甲基化模式的确定。(d)表征大的结构变体以鉴定新的调节元件。总之,我们的目标是确定因素和功能基因组区域,调节基因组印迹和印迹基因的表达。我们将确定表观基因组范围内的异常甲基化模式,以及在相同的检测中参与印记调控的染色体区域和因子。该分析将不限于特定的基因组区域,但该提案将涵盖患者及其父母的整个基因组。与转录组数据相结合,可以描绘干扰印迹的功能后果。这种方法将有助于了解的致病性ImpDis,但它也将被用于预防性的患者的临床管理。
英文摘要
Imprinting disorders (ImpDis) comprise congenital diseases which are characterised by disturbances of parentally imprinted genes. These genes are expressed either from the paternal or the maternal allele, and the disturbances consists of both genomic and epigenetic alterations. The clinical diagnosis of ImpDis is often hampered by the lack of clinical specifity, as the symptoms can overlap. ImpDis are caused by four different molecular changes: Three of them represent classical molecular changes, but epimutations comprise DNA modifications (e.g. 5-methylcytosine). The causes of epimutations are unknown in the majority of cases, but molecular alterations in imprinted regions themselves (cis factors) as well as in other genomic regions (trans factors) probably play a role. However, systematic approaches are currently missing, due to technical limitations as well as the rareness of ImpDis. With the implementation of NextGenerationSequencing and Longread-Sequencing techniques suitable assays are now available fort he comprehensive analyses of genomic, structural, epigenetic and transcriptional factors of epigenetic regulation and ist disturbances. This proposal combines second and third generation sequencing approaches with a unique cohort of patients with 11p15.5 and 14q32 epimutations to address genomic and epigenetic variations at allelic resolution in protein and nonprotein coding regions. The strategy to identify the molecular basis of ImpDis includes (a) Genome-wide analysis of methylation in carriers of 11p15.5 and 14q32 epimutations to identify multilocus imprinting disturbances (MLID) and to discriminate ImpDis subgroups. (b) Identification of genomic variants in cis and trans factors causing both MLID and isolated epimutations. (c) Determination of allele-specific methylation patterns on single molecule level over long distance covering whole differentially methylated regions at once. (d) Characterization of large structural variants to identify new regulating elements. Altogether, we aim to identify factors and functional genomic regions which regulate genomic imprinting and the expression of imprinted genes. We will both determine epigenomewide patterns of aberrant methylation as well as chromosomal regions and factors involved in the regulation of imprinting in the same assays. The analysis will not be restricted to specific genomic regions but the proposal will cover whole genomes of both the patients and their parents. In combination with transcriptome data functional consequences of disturbed imprinting can be delineated. This approach will help to understand the pathoetiology of ImpDis, but it will also be translationally used for clinical management of the patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Identification of molecular causes of human growth retardation in patients with features of Silver-Russell syndrome
  • 批准号:
    350540879
  • 项目类别:
    Research Grants
  • 资助金额:
    $0.0万
  • 财政年份:
    2017
  • 负责人:
    Professor Dr. Thomas Eggermann, Ph.D.
  • 依托单位:
海外基金